Lifeboat Foundation

It was a pleasure speaking to Dr. Ronald Kohanski at the 2019 Ending Age-Related Diseases conference. Dr. Kohanski joined the field of aging research in 2005 as a Program Officer for the Division of Aging Biology at the National Institute on Aging. He moved on to become its Deputy Director in 2007 and has held the position ever since. Within aging research, he has focused his efforts on the areas of stem cell and cardiovascular biology.

Besides his work at the NIA, Ronald Kohanski is a co-founder and co-leader of the trans-NIH Geroscience Interest Group (GSIG) with which he has organized several summits to discuss and disseminate the group’s focus. The GSIG directs its attention toward aging as the major risk factor for most chronic age-related diseases, and Dr. Kohanski actively encourages researchers to expand studies beyond laboratory animals. He underwrites the importance of addressing the basic biology of aging explicitly in human and non-laboratory animal populations. He believes that age should be considered a fundamental parameter in research that uses animal models of chronic disease.

Dr. Kohanski was trained in the field of biochemistry. He received his PhD from the University of Chicago in 1981, after which he conducted a postdoctoral fellowship with M. Daniel Lane at the Johns Hopkins University School of Medicine. He held a faculty position at the Mount Sinai School of Medicine for 17 years before returning to Johns Hopkins as a faculty member and researcher in the areas of enzymology and developmental biology of the insulin receptor.

Searching for new substances and developing new techniques in the chemical industry: tasks that are often accelerated using computer simulations of molecules or reactions. But even supercomputers quickly reach their limits. Now researchers at the Max Planck Institute of Quantum Optics in Garching (MPQ) have developed an alternative, analogue approach. An international team around Javier Argüello-Luengo, Ph.D. candidate at the Institute of Photonic Sciences (ICFO), Ignacio Cirac, Director and Head of the Theory Department at the MPQ, Peter Zoller, Director at the Institute of Quantum Optics and Quantum Information in Innsbruck (IQOQI), and others have designed the first blueprint for a quantum simulator that mimics the quantum chemistry of molecules. Like an architectural model can be used to test the statics of a future building, a molecule simulator can support investigating the properties of molecules. The results are now published in the scientific journal Nature.

Using hydrogen, the simplest of all molecules, as an example, the global team of physicists from Garching, Barcelona, Madrid, Beijing and Innsbruck theoretically demonstrate that the quantum simulator can reproduce the behaviour of a real molecule’s electron shell. In their work, they also show how experimental physicists can build such a simulator step by step. “Our results offer a new approach to the investigation of phenomena appearing in quantum chemistry,” says Javier Argüello-Luengo. This is highly interesting for chemists because classical computers notoriously struggle to simulate chemical compounds, as molecules obey the laws of quantum physics. An electron in its shell, for example, can rotate to the left and right simultaneously. In a compound of many particles, such as a molecule, the number of these parallel possibilities multiplies. Because each electron interacts with each other, the complexity quickly becomes impossible to handle.

As a way out, in 1982, the American physicist Richard Feynman suggested the following: We should simulate quantum systems by reconstructing them as simplified models in the laboratory from individual atoms, which are inherently quantum, and therefore implying a parallelism of the possibilities by default. Today, quantum simulators are already in use, for example to imitate crystals. They have a regular, three-dimensional atomic lattice which is imitated by several intersecting laser beams, the “optical lattice.” The intersection points form something like wells in an egg carton into which the atoms are filled. The interaction between the atoms can be controlled by amplifying or attenuating the rays. This way researchers gain a variable model in which they can study atomic behavior very precisely.

The 2019 Nobel Prize in Chemistry was awarded to John B. Goodenough (The University of Texas at Austin), M. Stanley Whittingham (Binghamton University, State University of New York), and Akira Yoshino (Asahi Kasei Corporation and Meijo University) “for the development of lithium-ion batteries”. With the creation and subsequent optimization of lithium-ion batteries to make them more powerful, lighter, and more robust, the seminal work of Goodenough, Whittingham, and Yoshino has had a profound impact on our modern society. This ubiquitous technology has revolutionized our daily lives by paving the way for portable electronics and made renewable energy sources more viable. While attempts to improve the performance of batteries continue, the lithium-ion battery has remained the world’s most reliable battery system for more than 40 years. The three winners will each receive an equal share of the roughly $1 million award. At 97, Goodenough is now the oldest person ever to win the Nobel Prize.

“A long-awaited recognition for the creators of lithium-ion batteries has come true. The electrochemistry and material science communities – and the greater chemistry community as a whole – are excited to hear the news of the 2019 Nobel Prize award to John B. Goodenough, M. Stanley Whittingham, and Akira Yoshino for their pioneering contribution to lithium-ion batteries,” said ACS Energy Letters Editor-in-Chief Prashant Kamat. “As we all know, the lithium-ion battery has revolutionized our modern-day activities. From mobile phones to laptops and from electronic gadgets to electric cars, these storage batteries have become part of our everyday life. We at ACS Publications are excited to be part of this celebration.”

Whittingham laid the foundation of the lithium-ion battery while working at Exxon in the 1970s. During that time, the oil crisis in the United States was ongoing, and there was a strong drive to develop methods of energy storage and transport that did not rely on fossil fuels. Whittingham developed a 2V lithium-ion battery based on a titanium disulfide cathode and lithium metal anode. While a seminal contribution to the advancement of the lithium battery, adopting Whittingham’s system for everyday use would be limiting due to the high reactivity of lithium metal and risk of explosion.

A team of Northwestern University researchers is the first to document the role chemistry will play in next generation computing and communication. By applying their expertise to the field of Quantum Information Science (QIS), they discovered how to move quantum information on the nanoscale through quantum teleportation—an emerging topic within the field of QIS. Their findings were published in the journal, Nature Chemistry, on September 23, 2019, and have untold potential to influence future research and application.

Quantum teleportation allows for the transfer of quantum information from one location to another, in addition to a more secure delivery of that information through significantly improved encryption.

The QIS field of research has long been the domain of physicists, and only in the past decade has drawn the attention and involvement of chemists who have applied their expertise to exploit the quantum nature of molecules for QIS applications.

As this new version of the periodic table underlines, we must do all we can to conserve and recycle the precious building blocks[…].

If we don’t start taking these problems more seriously, many of the objects and technologies that we now take for granted may be relics of a more abundant age a few generations from now – or available only to richer people.

It is amazing to think that everything around us is made up from just 90 building blocks – the naturally occurring chemical elements. Dmitri Mendeleev put the 63 of these known at the time into order and published his first version of what we now recognise as the periodic table in 1869. In that year, the American civil war was just over, Germany was about to be unified, Tolstoy published War and Peace, and the Suez Canal was opened.

Continue reading “Periodic table: new version warns of elements that are endangered” »

Schizophrenia is a severe mental health condition that causes significant disability, and affects 1 in 100 people. Patients with schizophrenia commonly experience negative symptoms, which include lack of motivation, social isolation and inability to experience pleasurable feeling. The current antipsychotics minimally improve these negative symptoms, and there are no currently licensed treatments. In addition, it is estimated that total service costs for schizophrenia in England alone will be £6.5 billion by 2026. In view of this, there is considerable interest in identifying potential treatment targets for these symptoms. However, the nature of the changes in brain chemistry that contribute to these negative symptoms is unknown.

Mu-opioid receptors (MOR) are found in a region of the brain called the striatum and they play a crucial role in how we experience pleasure and reward. Our bodies naturally produce opioid molecules that include endorphins; which are hormones secreted by the brain that are known to help relieve pain or stress and boost happiness. MORs are receptors that bind these naturally produced endogenous opioid molecules, and stimulation of the MOR system starts a signalling cascade that causes an increase in motivation to seek reward and increase food palatability amongst many other effects. Interestingly, MORs were found to be reduced in the striatum post-mortem in schizophrenia. So, it was unclear whether the availability of these receptors was increased when individuals were alive, or whether reduced MORs was related to the negative symptoms of schizophrenia.

The latest brain scan research from the Psychiatric Imaging group at the MRC LMS published on 3 October in Nature Communications has reported how the MOR system contributes to the negative symptoms displayed in schizophrenia patients. For the first time, this research study showed how MOR levels are significantly reduced in the striatum region of the brain. Thus, a lack of MOR system stimulation in the brain contributes to these negative feelings that schizophrenia patients can experience.

Never-before-seen chemical modifications set biochemists abuzz.

Checkerspot, a biotech startup using microalgae to produce performance materials, announced today that it has closed its Series A financing for $13 million. The round was led by Builders VC, and included Breakout Ventures, Viking Global Investors, KdT Ventures, Plug and Play Ventures, Sahsen Ventures, and Godfrey Capital, among others.

Checkerspot combines bioengineering, chemistry, and materials science to go from microalgae to next-generation performance materials.

“This is a pretty significant milestone for us,” said Checkerspot CEO Charles Dimmler. He said the funding would support the company’s continued infrastructure development, as well as ongoing commercial activities with Beyond Surface Technologies and DIC that focus on novel triglycerides and polyols. He also said it would help complete the development of a direct-to-consumer product later this year.

When I imagine the inner workings of a robot, I think hard, cold mechanics running on physics: shafts, wheels, gears. Human bodies, in contrast, are more of a contained molecular soup operating on the principles of biochemistry.

Yet similar to robots, our cells are also attuned to mechanical forces—just at a much smaller scale. Tiny pushes and pulls, for example, can urge stem cells to continue dividing, or nudge them into maturity to replace broken tissues. Chemistry isn’t king when it comes to governing our bodies; physical forces are similarly powerful. The problem is how to tap into them.

In a new perspectives article in Science, Dr. Khalid Salaita and graduate student Aaron Blanchard from Emory University in Atlanta point to DNA as the solution. The team painted a futuristic picture of DNA mechanotechnology, in which we use DNA machines to control our biology. Rather than a toxic chemotherapy drip, for example, a cancer patient may one day be injected with DNA nanodevices that help their immune cells better grab onto—and snuff out—cancerous ones.